In the evolving landscape of precision oncology, Caris Life Sciences has offered investors and clinicians alike a moment of measured confidence: a second quarter that exceeded expectations, margins that moved in the right direction, and a new diagnostic product entering the world. The company, which translates tumor biology into treatment guidance, raised its full-year outlook — a gesture that carries weight in a sector where promises often outpace performance. It is a story about what happens when the science of personalized medicine begins to find its economic footing.